Dr. Faubel nailed the best comment about NephroCheck by reminding us while we pick apart the particulars of NephroCheck that we have some other dragons to slay:
And then Edgar slides in with the appropriate #NephPearl (How does he do that so fast?)
Summary of the CAPTIVATE platform which will be a twitter spaces discussion
This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
Dr. Faubel nailed the best comment about NephroCheck by reminding us while we pick apart the particulars of NephroCheck that we have some other dragons to slay:
@hswapnil @Nephro_Sparks @dr_nikhilshah btw, nephrocheck and urine eos cost about the same. urine eos useless. this much better. #nephjc
— sarah faubel (@doc_faubel) February 18, 2015
And then Edgar slides in with the appropriate #NephPearl (How does he do that so fast?)
@NephJC @doc_faubel Why I DO NOT order URINE EOSINOPHILS anymore #Nephpearls #NephJC http://t.co/NH9PdFK7fc pic.twitter.com/cbneNsoZPl
— Edgar V. Lerma (@edgarvlermamd) February 18, 2015
We had a great NephJC last night. We had a new contributor who was excellent, Eric Weinhandl of Minnesota.
those models for ESRD risk are like spinning plates. 31 events and HRs bounce around with every adjustment #nephjc
— Eric Weinhandl (@EWeinhandl) February 4, 2015
Dr. Weinhandl works with the new PEER Kidney Care Initiative. It looks like a cool project. Here is some press from Nephrology News and Issues.